Table 1 Characteristics of the included studies
Study | Year | Region | Tumor type | Sample size (low/high) | HR (95% CI) | Outcome | Method | Follow-up months | NOS |
|---|---|---|---|---|---|---|---|---|---|
Li [18] | 2020 | China | NSCLC | 63 (31/32) | 0.44 (0.23, 0.84) | OS | qRT-PCR | 60 | 7 |
Yang [13] | 2019 | China | CRC | 135 (43/92) | 0.36 (0.16, 0.81) | CP, OS | qRT-PCR | 60 | 7 |
Zhao [26] | 2019 | China | OSCC | 73 (37/36) | 0.63 (0.35, 1.13) | CP, OS | qRT-PCR | 60 | 7 |
Hao [19] | 2020 | China | ccRCC | 66 (33/33) | 0.55 (0.28, 1.08) | CP, OS | qRT-PCR | 60 | 7 |
Liang [17] | 2021 | China | GC | 36 (18/18) | 0.47 (0.24, 0.92) | OS | qRT-PCR | 60 | 6 |
Qin [16] | 2021 | China | GC | 98 (49/49) | 0.36 (0.13, 1.00) | CP, OS | qRT-PCR | 36 | 6 |
Zhang [27] | 2020 | China | ccRCC | 76 (38/38) | 0.33 (0.09, 1.19) | OS | qRT-PCR | 60 | 7 |
Tu [20] | 2021 | China | OSC | 40 (21/19) | 0.33 (0.09, 1.21) | OS | qRT-PCR | 60 | 6 |
Wei [15] | 2019 | China | SKCM | 54 (27/27) | 2.97 (1.64, 5.36) | CP, OS | qRT-PCR | 105 | 7 |